Alzheimer Disease

Part I: Pathogenesis and Therapeutics

by

Prof. K. K. Jain
MD, FRACS, FFPM
Jain PharmaBiotech
Basel, Switzerland

November 2021

A Jain PharmaBiotech Report

AUTHOR'S BIOGRAPHY

Professor K. K. Jain is a neurologist/neurosurgeon with specialist qualifications including Fellowships of the Royal Colleges of Surgeons in Australia and Canada. He has trained, practiced, and held academic positions in several countries including Switzerland, India, Iran, Germany, Canada, and USA. After retirement from neurosurgery, Prof. Jain remains a consultant in neurology. He is also working in the biotechnology/biopharmaceuticals industry and is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of UK. Currently, he is the CEO of Jain PharmaBiotech.

Prof. Jain's 490 publications include 35 books (6 as editor+ 29 as author) and 50 special reports, which have covered important areas in biotechnology, gene therapy and biopharmaceuticals, biomarkers: proteomics, molecular diagnostics, nanobiotechnology, and personalized medicine. Contributions to MedLink, an accredited continuing education program for neurologists, include 172 articles out of a total of 1200 articles by 450 authors. These articles are updated on a yearly basis.

Prof. Jain's earlier books were the first in the areas covered: "Handbook of Laser Neurosurgery" (Charles C. Thomas, Springfield, Ill, 1983) and "Textbook of Hyperbaric Medicine" (1st ed in 1990 and 6th ed by Springer, 2017). His "Textbook of Gene Therapy" was translated into Chinese in 2000. Recent books include "Handbook of Nanomedicine" (Springer 2008, Chinese edition by Peking University Press 2011, 3rd ed 2017), "Textbook of Personalized Medicine" (Springer 2009; Japanese ed 2012; 2nd ed Springer 2015, 3rd ed 2021), "Handbook of Biomarkers" (Springer 2010; Chinese ed, Chemical Industry Press 2016, 2nd ed 2017), "Drug-induced Neurological Disorders", 4th ed (Springer 2021), "Handbook of Neuroprotection" (Springer 2011, 2nd ed 2019), "Applications of Biotechnology in Cardiovascular Therapeutics" (Springer 2011), "Applications of Biotechnology in Neurology" (Springer 2013), and "Applications of Biotechnology in Oncology" (Springer 2014). He has also edited 3 editions of "Drug Delivery System" (Springer 2008, 20012 and 2018) and "Applied Neurogenomics" (Springer 2015). Lectures on personalized medicine given at Kazakh National Medical University, Kazakhstan were translated into Russian and published as a book "Essentials of Personalized Medicine" (LITERRA Publishing House, Moscow, 2019). He is currently writing "The Handbook of Alzheimer Disease" to be published by Springer in 2022.

November 2021 (first edition in 2003)
Copyright © 2021 by

Jain PharmaBiotech
Bläsiring 7
CH-4057 Basel
Switzerland

Tel & Fax: **+4161-6924461**
Email: **info@pharmabiotech.ch**
Web site: **http://pharmabiotech.ch/**

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, or otherwise without the prior written permission of the Publisher. This report may not be lent, resold or otherwise traded in any manner without the consent of the Publisher. While all reasonable steps have been taken to ensure the accuracy of the information presented, the Publisher cannot accept responsibility for inadvertent errors or omissions.

T A B L E O F C O N T E N T S

0. Executive Summary 17

1. Clinical Features, Epidemiology and Pathology 19

Introduction 19
Historical aspects 19
Clinical features of Alzheimer disease 20
Seven stages of Alzheimer disease 22
AD as a terminal illness 24
Detection of AD in the preclinical phase 24
Differentiation of AD from other dementias 24
Differentiation of AD from non-dementing disorders 25
Cerebral insufficiency and AD 26
Memory deficits and preclinical AD 26
Sleep disorders and AD 27
Circadian rhythms and sleep in AD 27
Sleep duration and AD 28
Mild cognitive impairment 28
Evolution of diagnostic criteria of AD 30
Revised criteria for the clinical diagnosis of AD 31
Epidemiology 32
Epidemiology of aging 32
Epidemiology of dementia 34
Epidemiology of AD 35
Prevalence of AD according to age 35
Mortality in AD 35
Pathophysiology of AD 35
Cerebral atrophy and neuronal loss 35
Neuritic plaques and neurofibrillary tangles 36
See-through 3D imaging of the AD brain 36
Sp proteins as biomarkers of neuronal death in AD 37
Role of tau in the pathogenesis of AD 37
RNA-binding proteins and AD 39
Amyloid precursor protein 40
APP intracellular domain 40
Relation of APP mutations to CNS disorders 40
Relation of APP to Aβ deposits and pathogenesis of AD 41
Role of neprilysin in Aβ degradation 42
Role of secretases in amyloid cascade 42
Role of exosomal proteins 44
Role of nicastrin 44
Neurotoxicity of Aβ deposits 44
Aβ production and clearance 46
Aβ-mediated synaptic and cognitive deficits 47
Dysfunction of TGF-β signaling accelerates Aβ deposition 47
Interaction of Aβ with neuron-specific Na+/K+-ATPase α3 subunit 48
Relation of Aβ deposits to synaptic activity 48
Role of TMP21 in presenilin complexes and Aβ formation 48
Role of Aβ dimers in the pathogenesis of AD 49
Role of dsDNA breaks in neurodegeneration due to Aß 49
Structure–neurotoxicity relationships of Aβ oligomers 49
Sequence of events in neurotoxicity of Aβ 50
AD as an ion channel disorder 51
Neural thread protein 52
Loss of synaptic proteins 52
AD and Down syndrome 52
AD and age-related macular degeneration 53
Blood-brain barrier in AD 53
Blood vessel damage in AD 54
Fibrinogen-induced loss of synapses 54
Loss of serotonin 1A receptors in the brain 55
Myelin hypothesis of AD 55
Overlapping pathologies of AD and Parkinson disease 55
Factors in pathogenesis of AD 56
Astrocytes and AD 56
Axonal transport failure in AD 56
Cell-cycle hypothesis 57
Chronic heart failure link with AD 57
Creatine and AD 57

Disturbances in brain metabolism in early AD *57*
Disturbance of lipid metabolism in the brain *58*
DENN/MADD expression and enhanced pro-apoptotic signaling in AD *58*
Dopamine and AD *59*
Functioning role of genes in pathomechanism of AD *59*
Gonadotrophins and AD *59*
Glutamate transport dysfunction in AD *60*
Herpes simplex virus type 1 and AD *61*
Innate immune system and AD *61*
Insulin, diabetes and AD *61*
Mechanisms underlying cognitive deficits in AD *63*
Microglia and AD *64*
Monoamine oxidase and AD *64*
Neuroinflammation and AD *65*
Neurotransmitter deficits *66*
Neurotrophic factors *67*
NF-κB signaling and the pathogenesis of neurodegeneration *67*
Nitric oxide and AD *67*
Nogo receptor pathway *70*
Oxidative stress and AD *70*
Prostaglandins and AD *72*
Quinolinic acid and AD *72*
Retromer deficiency *72*
Serotonin and AD *73*
Spread of neurodegeneration 73
Synaptic failure in AD *73*
Transmission of AD *74*
Ubiquitin-proteasome system in pathogenesis of AD *75*
Risk factors in the etiology of AD 76
Aging and developmental abnormalities of the cholinergic system *76*
Cholesterol, dietary lipids, and Aβ *77*
Epigenetic link between aging and AD *78*
Exposure to magnetic fields *78*
Family history of AD *78*
Homocysteine and AD *78*
Hypertension and AD *79*
Level of education/type of job and risk of AD *79*
Metals and AD *80*
Obesity *81*
Proneness to psychological distress and risk of AD *82*
Reduced muscle strength *82*
Sleep deprivation *83*
Traumatic brain injury and AD *83*
Vascular risk factors for AD *84*
Vitamin B12 and folate *86*
AD versus non-dementing changes in the aging brain 86
AD and cognitive impairment with aging 86
Pathomechanism of memory impairment and AD 87
Concluding remarks on pathophysiology of AD 87
Genetics of AD 89
Familial AD 89
Molecular genetics of familial AD *89*
Presenilins and calcium channel pathogenesis of familial AD *90*
Presenilin-1 mutations and familial AD *90*
Late onset AD 91
Genomics of AD 92
Introduction to genomics 92
Genes associated with Alzheimer disease 92
AlzGene database *94*
ApoE genotype and nitric oxide *94*
ApoE genotype modulates AD phenotype *94*
APOE genotype and age-related myelin breakdown *95*
ApoE receptor interaction with NMDA receptor *95*
ApoE and ApoER2 ..... *95*
ApoE receptor LR11 as regulator of Aβ *96*
Arctic mutation *96*
BCHE gene *96*
BRCA1 and AD *96*
CALHM1 polymorphism and AD *97*
CD2AF and AD *97*
CLU, CRI and PICALM *97*

Genetic variants associated with early-onset AD 98
Genetic variants associated with late-onset AD 98
ApoE polymorphisms associated with LOAD 98
BMI1 mutations 100
Copy number variation (CNV) in LOAD 100
CYP46 and risk for AD 100
DAPK1 gene variants and AD 100
LRRTM3 as a candidate gene for AD 101
MTHFD1L gene variant associated with AD 101
Mutation in APP gene with protective effect against AD 101
OGG1 mutations associated with AD 102
SORL1 gene in AD 102
TOMM40 gene and risk of AD 102
TREM2 variants in AD 102
International Genomics of Alzheimer's Project 103
Sequencing in Alzheimer disease 103
Whole genomic sequencing in AD 104
Single-cell RNA sequencing in AD 105
Molecular neuropathology 105
Gene recombination in AD 105
Role of microRNAs in AD 106
DNA methylation in AD 107
AD as a polygenic disorder 107
Proteomics of AD 108
Introduction 108
Application of proteomic technologies to study AD 108
Disturbances of interaction of nervous system proteins 110
Protein misfolding in AD 111
Common denominators of AD and prion diseases 111
Metabolomics of AD 112
Glucose hypometabolism in AD 112

2. Diagnostic Procedures for Alzheimer Disease 113

Importance of the diagnosis of Alzheimer disease 113
Methods of diagnosis of AD 113
Self-administered olfactory test 114
Neuropsychological testing 114
Assessment and evaluation 115
7-minute screen 115
15-point risk index 116
Activities of Daily Living 116
Alzheimer Disease Cooperative Study 116
Artificial intelligence-based test for diagnosis of AD 116
CDR-SOB score 116
Clinician's Interview-Based Impression of Change 117
DETECT™ System 117
Measurement of aggregation in anterior segment of the eye 117
Resource Utilization in Dementia Battery 117
SymptomGuide™ 118
Electrophysiology 118
Quantitative EEG for investigation of early AD 118
EEG-based bispectral index 118
Event-related potentials 118
Correlation of electrical activity of the brain with cognition 119
Concluding remarks on the role of EEG in diagnosis of AD 119
Ocular findings for the diagnosis of AD 119
The pupillary light reflex test for AD 120
Early detection of cataract associated with AD 120
Retinal imaging to detect Aβ deposits 120
Laboratory methods for diagnosis of AD 121
Examination of cerebrospinal fluid 121
Monitoring of synthesis and clearance rates of Aβ in the CSF 121
Molecular diagnostics for AD 122
Genetic tests for AD 123
ApoE genotyping 124
Gene expression patterns in AD 124
Monoclonal antibody-based in vitro diagnosis of AD from brain tissues 124
Multi-tissue RNA signature of aging as diagnostic for AD 124
Biomarkers of AD 125
The ideal biomarker for AD 127
CSF biomarkers of AD 128

CSF sulfatide as a biomarker for AD *128*
Glial fibrillary acidic protein in AD *128*
Glycerophosphocholine as CSF biomarker in AD *129*
Protein biomarkers of AD in CSF *129*
Tau proteins in CSF *131*
Tests for the detection of Aβ in CSF *131*
Tests combining CSF tau and Aβ *132*
Lumipulse G CSF assays for routine diagnosis of AD *132*
Neurogranin as a cognitive biomarker in AD *133*
Concluding remarks about CSF biomarkers of AD *133*
Urine tests for AD 133
Blood tests for AD 134
A serum protein-based algorithm for the detection of AD *134*
α2-macroglobulin as a biomarker of preclinical and early AD *134*
Blood Aβ level as biomarker of AD *134*
Blood concentrations of tau and neurofilament light chain *135*
Blood test for AD based on heme oxygenase-1 ..... *136*
Blood test for AD based on RNA hybridization *136*
GSK-3 elevation in white blood cells *136*
Lipid biomarkers for preclinical detection of AD *137*
Lymphocyte Proliferation Test *137*
Metabolomic biomarker profiling *137*
MGAT3 as biomarker for prognosis of AD *137*
MicroRNA-based test for AD *138*
Protein kinase C in red blood cells *138*
Sphingolipids *138*
Tests based on multiple protein biomarkers in blood *139*
Skin test for early detection of AD 139
Saliva-based tests for AD 140
Saliva Aβ42 level as a biomarker of AD *140*
Smell identification test 140
Nanotechnology to measure Aβ-derived diffusible ligands 140
Simultaneous measurement of several biomarkers for AD 141
Nutritional biomarkers in plasma of AD patients 142
Plasma biomarkers of drug response in AD 142
Biomarkers of disease modifying therapies for AD 142
Concluding remarks about biomarkers for AD 143
Imaging in AD 143
Computed tomography 143
Magnetic resonance imaging 144
Arterial spin labeling with MRI *145*
Magnetic resonance microscopy *145*
Magnetic resonance spectroscopy *145*
Single photon emission computed tomography and modifications 146
Positron emission tomography 146
In vivo imaging of Aβ deposits by PET 148
Pittsburgh compound B and PET *148*
Florbetapir-PET *149*
Florbetaben-PET *150*
Flutemetamol-PET *150*
Future prospects of the PET imaging in AD *151*
In vivo detection of Aβ plaques by MRI 151
Imaging agents for Aβ and neurofibrillary tangles 152
Hyperspectral Raman imaging of neuritic plaques in AD 152
Targeting of a chemokine receptor as biomarker for brain imaging 153
Radioiodinated clioquinol as a biomarker for Aβ 153
In vivo imaging of tau by PET 153
Imaging neuroinflammation in AD by PET 154
Preclinical diagnosis of AD 154
Correlation of imaging with CSF biomarkers for early detection of AD *155*
Meta-analysis of literature on imaging in AD 155
Alzheimer Disease Neuroimaging Initiative 156
Computer aided diagnosis systems for AD based on imaging data 156
Concluding remarks on imaging for diagnosis of AD 157
Diagnosis of MCI and prediction of AD 158
Diagnosis of MCI 158
Computer-Administered Neurophychological screen for MCI *158*
Infrared eye-tracking technology to detect MCI *158*
MRI for detection of MCI *159*
PET for detection of MCI *159*
Role of APOE genotype in early MCI *159*

Presymptomatic detection of AD 159
Biomarkers for AD screening 160
Biomarker changes in autosomal dominantly inherited AD 160
Blood test for preclinical diagnosis of AD 160
Gait analysis during cognitive tasks 161
Genetic screening for AD 161
PredictAD project 161
Prediction of AD in patients with MCI 162
Biochemical biomarkers in CSF for prediction of AD 162
Clinical and biochemical biomarkers for profiling prodromal AD 162
Combination of MMSE and a memory test for prediction of AD 162
Plasma protein biomarkers of conversion of MCI to AD 163
MRI for prediction of AD 163
Magnetoencephalography for detection of MCI and AD 163
MRI-based index to measure the severity of AD in MCI 164
Concluding remarks about prediction of AD in MCI 164
Criteria for diagnosis of AD 164
Role of biomarkers in diagnosis of AD dementia 165
Ethical aspects of diagnostics for AD 167
Genetic testing for AD 167
Ethical issues of brain imaging in AD 168
Monitoring of treatment of AD 168
Monitoring treatment of mixed AD and vascular dementia 168
Companies involved in diagnosis of AD 168

3. Management of Alzheimer Disease 170
Introduction 170
Cholinergic approaches 170
Mechanism of action of cholinesterase inhibitors 171
Choline and lecithin 172
Donepezil 173
Rivastigmine 174
Galantamine 175
Duration of treatment with ChE inhibitors 176
Comparative studies of ChE inhibitors 176
Donepezil versus rivastigmine 176
Donepezil versus galantamine 177
Combination of cholinesterase inhibitors and a cholinergic precursor 177
Assessment of future of anticholinergic therapies 178
Neuroprotection in Alzheimer's disease 178
Memantine 179
Pharmacology of memantine 179
Clinical trials of memantine 180
Combination of memantine with ChE inhibitors 182
Aducanumab 183
Pharmacology 183
Clinical trials of aducanumab 183
Adverse effects of aducanumab 184
Monoamine oxidase inhibitors 184
Selegiline 184
Synaptoprotection in AD 185
Drugs for noncognitive symptoms in AD 185
Antidepressants 185
Antipsychotics 185
ChE inhibitors for behavioral and psychological disorders in AD 186
Concluding remarks and other drugs for agitation in AD 187
Sensory stimulation 187
Nutritional therapies for AD 187
Axona 188
Cocktail of dietary supplements for AD 188
Docosahexaenoic acid 188
Ketogenic diet 190
Magnesium 190
Nicotinamide for the treatment of AD 190
Omega-3 fatty acids 191
Preventing decline of mental function with aging and dementia 192
Prevention of Alzheimer disease 193
Mental training 194
Physical exercise 194
Higher level of conscientiousness and decreased risk of AD 195
Nutritional factors in prevention of AD and MCI 196

Black and green teas ... *196*
Caffeine ... *196*
Caloric restriction ... *197*
Cinnamon ... *197*
Cocoa flavonol consumption ... *197*
Grapes and red wine ... *198*
Vitamin D and docosahexaenoic acid ... *199*
Drugs to prevent Alzheimer disease ... 199
Preimplantation genetic diagnosis of inherited Alzheimer disease ... 199
Presymptomatic detection of AD for implementing prevention ... 200
Clues from PET scans of patients with Down syndrome ... *200*
Preclinical biomarkers of AD ... *200*
Management of mild cognitive impairment ... **200**
Slowing the progression of MCI to AD ... 201
Management of Down syndrome ... **202**
Guidelines for use of anti-dementia drugs in clinical practice ... **202**
Donepezil and/or memantine ... 203
General care of the Alzheimer disease patients ... **204**
Strategies for the management of Alzheimer disease ... **204**

4. Research in Alzheimer Disease ... 206
Introduction ... **206**
Animal models of Alzheimer disease ... **206**
Lesional models ... 206
Cerebroventricular injection of Aβ in rats ... *206*
Lentiviral vector-based models of amyloid pathology ... *207*
AAV-mediated gene transfer to increase hippocampal Aβ ... *207*
Cholesterol-fed rabbits as models for AD ... 207
Canine dementia as model for AD ... 207
Herpes-induced AD brain model ... 208
Transgenic mouse models ... 208
Quantitative assessment of amyloid load in transgenic models ... *209*
In vivo magnetic resonance microimaging in transgenic models of AD ... *210*
Transgenic model of AD with suppression of Aβ production ... *210*
Transgenic AD11 anti-NGF mice ... *210*
Genetically altered mice with deficiency of vesicular ACh transporter ... *211*
Limitations of transgenic mouse models of Alzheimer disease ... *211*
Improved mouse models of AD expressing human genes ... *212*
Transgenic invertebrate models of Alzheimer disease ... 212
Drosophila model of AD ... *212*
Caenorhabditis elegans Alzheimer disease model ... *213*
Zebrafish model for AD ... 213
Correlation of studies in animal models and human clinical trials ... 214
Cell systems for AD research ... **215**
In vitro neuronal cell Lines ... 215
Single-gene expression system for use in cell culture ... 215
Stem cells for testing efficacy of AD drugs ... 216
Transgenic cells ... 216
In silico models ... 216
Estimation of progression rates of Alzheimer disease ... **217**
Clinical trial methods in Alzheimer disease ... **217**
Molecular imaging as a guide to drug development ... 218
Use of MRI and PET in clinical trials ... 218
Cognitive-function assessment in clinical trials ... 219
Clinical trials in mild cognitive impairment ... 219
Research in AD as a basis for future therapies ... **220**
Use of microarrays for studying pathogenesis of AD ... 220
Computational brain mapping in AD ... 220
Study of neurogenesis in AD ... 220
Study of 3D structure of Aβ ... 221
Solid-state NMR to study precursors of Aβ ... 221
Research in Alzheimer disease at academic centers ... **221**
Role of NIH in AD research ... 221
NIH Clinical Trials Database for AD ... 222
Alzheimer Research Consortium ... 222
The National Institute on Aging and AD research ... 222

5. Drug Discovery & Development for Alzheimer Disease ... 223
Introduction ... **223**
Categories of drugs in development for AD ... **223**
Memory-enhancing drugs ... **225**

Enhancing memory by drugs that block eIF2α phosphorylation 226
Drugs based on cholinergic approaches 226
AP2238 226
Butyrylcholinesterase inhibitors 226
Donepezil-tacrine hybrids 227
Drugs modulating gamma-aminobutyric acid receptors 227
Ganstigmina 228
Methanesulfonyl fluoride 228
Muscarinic receptor modulators 228
Muscarinic M1 agonists 229
Muscarinic M2 antagonists 229
Nicotine and nicotinic receptor modulators 230
Nicotine 230
Nicotinic receptor modulators 231
Ispronicline 232
JWB1-84-1 232
Neuropeptide/neurotransmitters 233
Somatostatin release enhancers 233
Glutamate receptor modulators 233
Physiology and pharmacology of glutamate receptors 234
NMDA receptor ion channel complex 234
Metabotropic glutamate receptors 235
Glutamate receptor modulators as potential therapeutics for AD 236
N20C 236
AMPA modulators 237
Glutamate release inhibitors 238
INI-0602 238
Drugs affecting multiple neurotransmitters 238
Ensaculin 238
RS-1259 238
Lecozotan 238
Inhibition of amyloid precursor protein aggregation 239
Secretase modulators 239
Neuroprotection by α-secretase cleaved APP 240
Inhibitors of β-secretase 241
Inhibitors of γ-secretase 242
Amyloid-derived diffusible ligands 243
GABA receptor modulation by etazolate and APP processing 243
Depletion of serum amyloid P 244
Drugs that inhibit the formation of Aβ 244
22R-hydroxycholesterol 244
Acylaminopyrazole 245
Cadmium telluride nanoparticles prevent Aβ fibril formation 245
Cannabinoids 245
Chelation therapy for AD 246
Clioquinol and PBT2 246
Copper chelation by FKBP52 248
Zinc chelation from amyloid plaques 248
Next generation multifunctional chelating agents for AD 248
Heparin and its derivatives 249
A reassessment of the role of heparin in AD 249
Enoxaparin 250
Heparan sulfate 250
Imatinib mesylate 250
Laminin 250
Masitinib 251
NSAIDs 251
Flurbiprofen analogs with Aβ42-lowering action 252
Nitric oxide-donating NSAIDs 253
In vivo demonstration of the effects of NSAIDs on brain in AD 253
Paclitaxel 253
Phenserine 253
Tolserine 254
Platinum-based inhibitors of Aβ 254
Retro-inverso peptide inhibitor 254
Scyllo-cyclohexanehexol 255
Selective serotonin reuptake inhibitor 255
Small molecule drug discovery for inhibiting Aβ aggregation 255
Trojan-horse approach to prevent build-up of Aβ aggregates 256
Ubiquitin C-terminal hydrolase L1 256
Drugs to prevent the formation of NFTs 256

Tau suppression **257**
Anthraquinones 257
Anti-tau antibodies 258
Tau aggregation inhibitor rember™ 258
LMTX® 258
Microtubule stabilizers 258
ApoE4 as a therapeutic target in AD **258**
Strategies to prevent deposits and enhance clearance of Aβ **259**
4,5-dianilinophthalimide for disruption of $A\beta_{1-42}$ fibrils 260
ABCA1 overexpression to lower amyloid deposits 260
ANAVEX 2-73 260
Beta-sheet breakers 261
Bexarotene 261
Blocking ApoE/Aβ interaction to reduce Aβ plaques 261
CD33 inhibitors 262
Clearance of Aβ across the blood-brain barrier 262
Clusterin for clearance of Aβ 262
Enhanced PKCε activity promotes clearance of Aβ 263
Galantamine-induced Aβ clearance 263
Hemopheresis 263
Inhibitors of Aβ dehydrogenase 264
Intravenous immune globulin 264
Monoclonal antibodies for removal of Aβ 265
Crenezumab *265*
Donanemab *265*
Gantenerumab *266*
Solanezumab *266*
Nanotechnology for removal of Aβ deposits 267
Role of matrix metalloproteinases in clearance of Aβ 267
Serum amyloid P component depletion 267
Small molecule DAPH for clearance of amyloid 267
Tramiprosate prodrug ALZ-801 268
Companies developing Aβ-directed therapeutics for AD **268**
Nootropics **269**
Acetyl-L-carnitine 270
Cerebrolysin 270
Ergot derivatives 270
Lisuride *271*
Dihydroergocryptine *271*
Neuroprotective effect drugs not primarily developed for AD **271**
Antiepiletic drugs 272
Lamotrigine *272*
Levetiracetam *272*
Antiinflammatory and antimicrobial drugs 272
Dapsone *272*
Antimicrobial drugs against C. pneumoniae *273*
PPAR-gamma agonists *273*
Antidiabetic drugs 274
Insulin *274*
Metformin *274*
DPP-4 and Alzheimer disease in type 2 diabetes mellitus *275*
Antihypertensive drugs 275
Angiotensin-converting enzyme inhibitors *275*
Angiotensin receptor blockers *276*
Nilvadipine *276*
Antiretroviral drugs 276
Bexarotene 276
Dimebon 277
Drugs acting on estrogen receptors 278
Estrogen *278*
Raloxifene *279*
Granulocyte-macrophage colony-stimulating factor *279*
Gingipain inhibitors 279
Inhibitors of neuroinflammation 279
Ceramide *279*
CSP-1103 ..... *280*
Cyclophosphamide *280*
Etanercept *280*
Fingolimod *281*
Interferon beta-1a *281*
MW01-5-188WH *281*

Neurosteroids 282
Pregnenolone sulfate *282*
Dehydroepiandrosterone *282*
Lithium 283
MAO-B inhibitors 283
Ladostigil tartrate *283*
Memoquin 284
Methylene blue 284
Nilotinib 285
Nimodipine 285
Rapamycin 285
Saracatinib 286
Statins 286
Testosterone 287
Valproic acid 288
Future prospects of neuroprotection in AD 288
Targeting Cdk5 pathway *288*
Antioxidants 289
Colostrinin 289
Curcumin 290
Dehydroascorbic acid 290
Reservatrol 291
Synthetic catalytic scavengers 292
Vitamins 292
Vitamin E as antioxidant 292
Vitamin B for lowering homocysteine 292
Folic acid 293
Aminopyridazines 293
Nanobody-based drugs for AD 293
Nitric oxide-based therapeutics for AD 294
Nitric oxide mimetics 294
iNOS inhibitors for AD 294
Novel drugs for AD from natural resources 294
Berberine chloride 295
Centella asiatica 296
Ginko biloba 296
Huperzine-A 297
Hyperforin 297
Nostocarboline derived from cyanobacteria 297
Salvia 298
Securinega suffruticosa 298
Withania somnifera 298
ZT-1 298
Cholesterol and AD 299
ACAT inhibitors 300
Role of gene for cholesterol ester transfer protein 301
Cholesterol 24S-hydroxylase as a drug target for AD 301
Selectively increase of ApoA-I production 301
Neurotrophic factors 301
Brain derived neurotrophic factor 302
Insulin-like growth factor-1 302
Nerve growth factor 302
Neotrofin (AIT-082) 303
Limitations of the use of NTFs for AD 304
Short peptides derived from neurotrophins 304
Role of serotonin modulators in AD 304
Xaliproden 305
5-HT_{1A} receptor antagonists 305
5-HT_6 antagonists 305
5-HT_4 receptor agonists 306
Donecopride *306*
Restoration of factors deficient in the aging brain 306
Reversal of cognitive impairment in aging by activation of creb protein 306
Reversal of cognitive impairment in aging by GDF11 protein 307
Restoration of repressor element 1-silencing transcription factor 307
Combined therapeutic approaches to AD 307
Drug delivery for Alzheimer disease 308
Delivery of biologicals across the BBB 308
Delivery of thyrotropin-releasing hormone analogs by molecular packaging 309
Nanoparticle-based drug delivery for Alzheimer's disease 309
Transdermal drug delivery in Alzheimer's disease 310

Transdermal rivastigmine ... *310*
Intranasal delivery of therapeutics for AD ... 311
Intranasal delivery of tacrine ... *311*
Intranasal delivery of nerve growth factor to the brain ... *311*
Circadian rhythms and timing of cholinesterase inhibitor therapy ... 311
Clinical trials for AD ... 311
Ongoing clinical trials of AD ... 313
Concluding remarks on clinical trials of AD ... 321
Drug discovery for AD ... 322
Drugs acting on signaling pathways ... 322
Activation of GTPase signaling by Cytotoxic Necrotizing Factor 1 ... *322*
Drugs to reverse inhibition of the PKA/CREB pathway in AD ... *323*
Inhibition of the CD40 signaling pathway ... *323*
JNK pathway as a target ... *324*
Mitogen-activated protein kinase pathway as target ... *324*
Protein kinase C activators ... *324*
Electrophysiological detection of drug target for neuroprotection in early AD ... 325
Genomics-based drug discovery ... 325
High through screening for AD drug candidates ... 325
New chemical entities for AD by combining galantamine and memantine ... 326
Novel rivastigmine-hydroxycinnamic acid hybrids for AD ... 326
Novels targets/receptors for AD drug discovery ... 326
ATH-1017 ... *326*
Activation of cerebral Rho GTPases ... *326*
Activators of insulin-degrading enzyme ... *327*
Blockade of TGF-β-Smad2/3 signaling in peripheral macrophages ... *327*
Calcium channel blockers ... *327*
Calcineurin inhibitors ... *328*
Calpain inhibitors ... *328*
Casein kinase 1 ... *329*
Chemokines ... *329*
Drugs against arginine deprivation and immune suppression in AD ... *329*
Heat shock protein 90 inhibitors ... *330*
Histone deacetylase inhibitors ... *330*
Inhibition of PDK1 to slow progression of both AD and prion disease ... *330*
Melatonin ... *331*
Neurotrophic compound J147 ... *331*
NF-κB inhibitors ... *332*
Kinases and phosphatases as targets for AD therapeutics ... *332*
Neutral sphingomyelinase inhibitors ... *333*
Phosphodiesterase inhibitors ... *333*
Pin 1 as a target in AD ... *333*
Protein phosphatase 5 as a neuroprotective in AD ... *334*
Single drugs for multiple targets in AD ... *334*
Sodium oligomannate ... *335*
Src homology-containing protein-1 inhibitors ... *335*
Targeting GABAergic system ... *335*
TSPO ligands ... *335*
Type 5 cyclic nucleotide phosphodiesterase inhibitors ... *336*
Proteomics and drug discovery for AD ... 336
Small molecule compounds binding to neurotrophin receptor p75NTR ... 337
Targeting Vav in tyrosine kinase signaling pathway ... *337*
LM11A-31 as p75NTR ligand ... *338*

6. Innovative approaches to Alzheimer disease ... 339
Introduction ... 339
Cell therapy for AD ... 339
Choroid plexus epithelial cells for AD ... 339
Stem cell transplantation for AD ... 340
Autologous adipose tissue derived mesenchymal stem cells ... *340*
Neural stem cells transplantation ... *340*
Neuronal differentiation of implanted NSCs enhanced by drugs ... *340*
NSCs improve cognition in AD via BDNF ... *340*
Potential benefits of grafting NSCs in AD ... *341*
Use of autologous stem cells for dementia ... *341*
Gene therapy for AD ... 341
ApoE gene therapy ... 342
APPsα gene transfer for rescuing synaptic failure in AD ... *342*
FGF2 gene transfer in AD ... 342
Gene therapy for restoring brain cholesterol metabolism ... 343
Humanin gene therapy ... 343

Neprilysin gene therapy 343
NGF gene therapy 344
Targeting plasminogen activator inhibitor type-1 gene 345
Antisense approaches to AD 345
Antisense PNA in AD 345
Antisense tau in AD 346
RNAi approaches to AD 346
Development of miRNAs for AD therapy 347
Vaccines for AD 348
Active immunization with Aβ 348
AN-1792 vaccine 348
DNA vaccine for AD 349
Strategies to avoid undesirable effect of Aβ vaccination 350
Passive immunization in AD 351
Passive immunization with MAbs 351
Clinical trials of MAbs in AD 352
Delivery of the passive antibody directly to the brain 353
Systemic injection of MAbs to treat AD 353
Combination of Aβ immunotherapy and CD40-CD40L blockade 354
Shaping the immune responses elicited against Aβ 354
Delivery of AD vaccines 354
Gene vaccination 354
Modified Aβ nasal vaccine 355
Transdermal Aβ vaccination 355
Other vaccines for AD 356
Nasal vaccination with Proteosome™ adjuvant 356
T cell vaccination with glatiramer acetate adjuvant 356
Early start of immunotherapy for clearing Aβ plaques 357
Reversal of cholinergic dysfunction by anti-Aβ antibody 357
Immune modulation via Toll-like receptors to reduce Aβ 357
Mechanisms by which Aβ antibodies reduce amyloid accumulation in the brain 358
Perspectives on vaccines for AD 358
Companies involved in AD vaccines 360
Non-pharmacological treatments of AD 361
Non-invasive neuromodulation 361
Application of electrical fields for improvement of cerebral function 361
Exposure of the brain to electromagnetic fields for treatment of AD 361
High-frequency electromagnetic field treatment of AD 362
Photo-induced inhibition of Aβ accumulation in AD 362
Transcranial magnetic stimulation 362
Ultrasound-based treatments for AD 363
Ultrasound for removal of Aβ 363
Ultrasound-based brain stimulation 363
Ultrasound for opening the BBB 363
Mental training for management of memory loss in AD 363
Neurosurgical procedures for AD 364
Cerebrospinal fluid shunting 364
Deep brain stimulation 364
Microchip-based hippocampal prosthesis for AD 365
Omental transposition 366
Vagal nerve stimulation 366

7. Future and Regulatory Aspects of Alzheimer disease 369
Introduction 369
Personalized therapy of AD 369
Pharmacogenomics of Alzheimer disease 370
Biomarkers and companion diagnostics for AD 370
Genotyping and AD therapeutics 370
Incorporation of genetic diversity into mouse models of AD 371
Future for AD therapeutics 371
Regulatory aspects of drug development for AD 373
EMEA guidelines for drug development for AD 373
FDA guidelines for drug development for AD 373
FDA's accelerated approval pathway in early Alzheimer disease 374

Tables

Table 1-1: Historical landmarks relevant to Alzheimer disease 19
Table 1-2: Clinical features of Alzheimer disease 20
Table 1-3: Non-Alzheimer dementias 25
Table 1-4: A guide to evaluation for MCI due to AD 29

Table 1-5: NINCDS-ADRDA Criteria for diagnosis of Alzheimer disease 30
Table 1-6: 2011 Revised criteria for diagnosis of dementia due to Alzheimer Disease 31
Table 1-7: Relation of mutations in amyloid precursor protein to CNS disorders 40
Table 1-8: Risk factors for Alzheimer's disease 76
Table 1-9: Genes linked to AD 92
Table 1-10: Abnormalities of expression of brain proteins in Down's syndrome and AD 109
Table 2-1: Classification of methods of diagnosis of Alzheimer disease 113
Table 2-2: Neuropsychological test batteries and scales for Alzheimer's disease 114
Table 2-3: Available molecular diagnostic tests for Alzheimer disease 123
Table 2-4: Biomarkers of AD in blood and CSF 126
Table 2-5: Characteristics of an ideal biomarker for Alzheimer disease 127
Table 2-6: Role of biomarkers in diagnosis of AD dementia 166
Table 2-7: Potential applications of fluid biomarkers of Alzheimer disease 166
Table 2-8: Companies involved in the diagnosis/monitoring of Alzheimer disease 169
Table 3-1: Classification of treatments for Alzheimer disease 170
Table 3-2: Cholinergic approaches used in the treatment of Alzheimer disease 171
Table 3-3: Categories of neuroprotective agents for Alzheimer disease 179
Table 3-4: Strategies for prevention of Alzheimer disease 193
Table 3-5: Guidelines for the treatment of dementia 202
Table 4-1: Transgenic mouse models of Alzheimer disease 208
Table 4-2: Correlation of studies in animal models with human clinical trials 214
Table 5-1: Classification of therapies in development for Alzheimer disease 224
Table 5-2: Drugs for AD targeting nACh receptors 232
Table 5-3: Ionotropic glutamate receptors 233
Table 5-4: Classification of mGluRs 233
Table 5-5: Glutamate receptor modulators as potential therapeutic agents in AD 236
Table 5-6: Preclinical studies of secretase modulators 239
Table 5-7: Secretase modulators in clinical trials 240
Table 5-8: Companies developing Aβ-directed therapeutics for AD 268
Table 5-9: Innovative neuroprotective approaches for Alzheimer disease 271
Table 5-10: Herbal therapies for AD 295
Table 5-11: Novel drug delivery methods for Alzheimer disease therapies 308
Table 5-12: Clinical trials in Alzheimer disease 313
Table 5-13: Discontinued, failed or inconclusive clinical trials of Alzheimer disease 318
Table 6-1: Companies involved in developing vaccines for AD 360

Figures

Figure 1-1: Percentages of world population of people over the age of 65 according to more developed and less developed portions – 2000 to 2050. 32
Figure 1-2: Correlation between aging and AD in the US from 2000 to 2020 33
Figure 1-3: Prevalence of different types of dementia 34
Figure 1-4: Structure of tau in a brain with AD 38
Figure 1-5: Aβ deposits in the brain 45
Figure 1-6: Major pathological features of AD 46
Figure 1-7: Mechanisms of Aβ clearance 46
Figure 1-8: Pathways for Aβ-induced nerve cell death 51
Figure 1-9: Insulin signaling in Alzheimer disease and diabetes 63
Figure 1-10: Nitric oxide neurotoxicity and neuroprotection in relation to Alzheimer disease 69
Figure 1-11: Oxidative stress and Alzheimer disease 71
Figure 1-12: Role of proteosome inhibition in Aβ generation and neurodegeneration 75
Figure 1-13: Cholesterol-related pathways to AD 77
Figure 1-14: Pathomechanism of AD 88
Figure 2-1: Pathophysiology of biomarkers of AD in relation to the neuron 125
Figure 3-1: Metabolism of acetylcholine 172
Figure 3-2: Neuroprotective effective of galantamine in AD 176
Figure 3-3: Strategies for the management of Alzheimer disease 204
Figure 5-1: Therapeutic strategies based on amyloid hypothesis of AD 223
Figure 5-2: Activation of α7 nicotinic acetylcholine receptors 231
Figure 5-3: NMDA receptor ion channel complex. 235
Figure 5-4: Neurotoxicity due to misfolding of Aβ1-42 260
Figure 5-5: Effect of DPP-4 inhibitor on AD 275
Figure 5-6: Interactions of players in clinical trials of Alzheimer disease in the USA 313
Figure 5-7: Role of proteomics in drug discovery/development for Alzheimer disease 336
Figure 7-1: FDA industry interaction during drug development for AD 374
Figure 7-2: FDA's accelerated approval pathway in early Alzheimer disease 374